[Federal Register Volume 63, Number 126 (Wednesday, July 1, 1998)]
[Notices]
[Page 35933]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-17411]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct; Terry D. Reisine, Ph.D.
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has made a final finding of scientific misconduct in the
following case:
Terry D. Reisine, Ph.D., University of Pennsylvania: Based upon
``The Dean's Proposed Findings of Fact'' and ``Memorandum on Issues Not
Fully Addressed in Findings of Fact,'' forwarded to ORI by the
University of Pennsylvania, dated October 25, 1996 (Findings and
Memorandum), and ORI's oversight review of the evidence provided, ORI
finds that Terry D. Reisine, Ph.D., former Professor, Department of
Pharmacology, University of Pennsylvania, engaged in scientific
misconduct in biomedical research supported by Public Health Service
(PHS) grants.
Specifically, ORI finds that the Respondent falsified results
related to the measurement of cyclic AMP in cultured, transfected cells
by falsely representing in manuscripts and publications the number of
experiments conducted, and by falsifying and/or fabricating some of the
substantive data presented in those manuscripts and publications.
Moreover, ORI finds that the Respondent attempted to falsify data by
directing members of his laboratory to construct figures and tables
with false values in the preparation of manuscripts.
Dr. Reisine has entered into a Voluntary Exclusion Agreement with
ORI. The settlement is not an admission of liability on the part of the
Respondent, and Dr. Reisine denies having committed scientific
misconduct. Pursuant to the Agreement, Dr. Reisine has agreed to the
following:
(1) Respondent agreed to exclude himself voluntarily for a period
of three (3) years beginning on June 11, 1998, from any contracting or
subcontracting with any agency of the United States Government, and
from eligibility for or involvement in nonprocurement transactions
(e.g., grants and cooperative agreements) of the United States
Government as defined in 45 CFR part 76 (Debarment Regulations).
(2) Respondent agreed to exclude himself voluntarily from serving
in any advisory capacity to PHS including, but not limited to, service
on any PHS advisory committee, board, and/or peer review committee, or
as a consultant for a period of three (3) years, beginning on June 11,
1998.
(3) Within 30 days of the effective date of the Agreement,
Respondent agreed to submit letters to the following journals
requesting correction of the corresponding articles. The corrections
are warranted by the following findings of the Findings and Memorandum:
a. The Journal of Biological Chemistry
Kong, H., Raynor, K., Yasuda, K., Moe, S.T., Portoghese, P.S., Bell,
G.I., and Reisine, T. ``A single residue, aspartic acid 95, in the
gamma opioid receptor specifies selective high affinity agonist
binding.'' J. Biol. Chem. 268:23055-23058, 1993.
i. The results in Table 1 are stated in the table legend to be
based on four (4) experiments with calculated SEM values and Hill
coefficients when, in fact, the majority of the listed compounds
were tested only once, and a few tested only twice.
ii. Figure 2 data are stated in the figure legend to be the
means of three (3) different experiments when, in fact, most of the
results were based on a single experiment.
b. The Journal of Pharmacology and Experimental Therapeutics
Raynor, K., Kong, H., Hines, J., Kong, G., Benevoc, J., Yasuda, K.,
Bell, G.I., and Reisine, T. ``Molecular mechanisms of agonist-
induced desensitization of the cloned mouse kappa opioid receptor.''
J. Pharmacol. Exp. Ther. 270:1381-1386, 1994.
i. The figure legend for Figures 3A, 3C, and 3D claimed that the
values shown were the average of three (3) different experiments
when, in fact, the results were from only one (1) experiment.
ii. The figure legend for Figure 4B claimed that the values
shown were the average of four (4) different experiments when, in
fact, the results were from only three (3) experiments.
iii. Figures 3A, 3C, and 3D each show several levels of adenyl
cyclase inhibition that do not reflect the actual results obtained
in duplicate cyclic AMP assays.
c. Molecular Pharmacology
Reisine, T., Kong, H., Raynor, K., Yano, H., Takeda, J., Yasuda, K.,
and Bell, G.I. ``Splice variant of the somatostatin receptor 2
subtype, somatostatin receptor 2B, couples to adenylyl cyclase.''
Mol. Pharmacol. 44:1016-1020, 1994.
i. The legend for Figure 3A claims that three (3) experiments
were performed when, in fact, only two (2) experiments were
performed for the SSTR2B mutants.
ii. The legend for Figure 3B claims that the values presented
are the average of two (2) different experiments when, in fact, the
inhibition curve shown was based on a single experiment.
FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research
Investigations, Office of Research Integrity, 5515 Security Lane, Suite
700, Rockville, MD 20852, (301) 443-5330.
Dorothy K. Macfarlane,
Acting Director, Office of Research Integrity.
[FR Doc. 98-17411 Filed 6-30-98; 8:45 am]
BILLING CODE 4160-17-P
